TIAA CREF Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$46.2M	Buy	524,465 +293,210	+127%	+$24.5M	0.03%	427
2018 Q4	$16.5M	Sell	231,255 -95,643	-29%	-$9.16M	0.01%	717
2018 Q3	$40.2M	Buy	326,898 +4,655	+1%	+$528K	0.03%	506
2018 Q2	$31.7M	Buy	322,243 +14,425	+5%	+$1.29M	0.02%	578
2018 Q1	$25.5M	Sell	307,818 -44,298	-13%	-$3.74M	0.02%	653
2017 Q4	$27.3M	Buy	352,116 +44,642	+15%	+$3.05M	0.02%	641
2017 Q3	$18.8M	Sell	307,474 -21,561	-7%	-$1.14M	0.01%	787
2017 Q2	$15.1M	Buy	329,035 +57,371	+21%	+$2.78M	0.01%	895
2017 Q1	$11.8M	Buy	271,664 +39,717	+17%	+$1.7M	0.01%	1014
2016 Q4	$8.98M	Buy	231,947 +49,982	+27%	+$2.26M	0.01%	1194
2016 Q3	$9.21K	Buy	181,965 +8,775	+5%	+$437K	0.01%	1178
2016 Q2	$7.87M	Sell	173,190 -178,008	-51%	-$8.2M	0.01%	1218
2016 Q1	$13.9M	Buy	351,198 +24,842	+8%	+$986K	0.01%	885
2015 Q4	$18.5M	Buy	326,356 +21,179	+7%	+$1.08M	0.01%	785
2015 Q3	$12.1M	Buy	305,177 +13,698	+5%	+$662K	0.01%	946
2015 Q2	$13.9M	Buy	291,479 +5,579	+2%	+$237K	0.01%	939
2015 Q1	$11.4M	Buy	285,900 +17,523	+7%	+$627K	0.01%	1060
2014 Q4	$6M	Sell	268,377 -33,034	-11%	-$626K	﹤0.01%	1499
2014 Q3	$4.72M	Sell	301,411 -7,351	-2%	-$110K	﹤0.01%	1659
2014 Q2	$4.58M	Buy	308,762 +14,726	+5%	+$208K	﹤0.01%	1750
2014 Q1	$4.73M	Buy	294,036 +7,511	+3%	+$128K	﹤0.01%	1653
2013 Q4	$2.68M	Hold	286,525	–	–	﹤0.01%	2074
2013 Q3	$3.24M	Sell	286,525 -7,318	-2%	-$101K	﹤0.01%	1900
2013 Q2	$3.93M	Buy	+293,843	New	+$3.61M	﹤0.01%	1695